{"schema_version":"secwatch.filing_event.v1","accession":"0001730463-25-000010","form_type":"8-K","ticker":"AUTL","cik":"0001730463","company_name":"Autolus Therapeutics plc","filed_at":"2025-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.648565+00:00","generated_at":"2026-05-24T10:26:49.530659+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Autolus reports FY2024 net loss $220.7M; AUCATZYL launch on track with 33 U.S. centers","bullets":["Net loss $220.7M ($0.86 per share) vs $208.4M ($1.20) in 2023; revenue $10.1M (up from $1.7M).","Cash and marketable securities $588M at Dec 31, 2024, up from $239.6M, boosted by BioNTech deal and equity financing.","AUCATZYL commercial launch: 33 authorized treatment centers (covering ~60% of target U.S. patients); targeting 60 by end-2025.","Obe-cel under EMA/MHRA review with decisions expected H2 2025; Phase 1 SLE trial fully enrolled (6 patients), data at April R&D event.","BioNTech option for AUTO1/22 expired Feb 8, 2025, not exercised; Blackstone $30M milestone payment triggered by FDA approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001730463-25-000010","json":"https://secwatch.observer/filing/0001730463-25-000010.json","markdown":"https://secwatch.observer/filing/0001730463-25-000010.md","text":"https://secwatch.observer/filing/0001730463-25-000010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730463/000173046325000010/0001730463-25-000010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730463/000173046325000010/autl-20250320.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T10:26:49.530659+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}